Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Short-term Investments (2024 - 2025)

Historic Short-term Investments for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $7.4 million.

  • Prelude Therapeutics' Short-term Investments fell 9478.92% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year decrease of 9478.92%. This contributed to the annual value of $121.1 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Prelude Therapeutics reported Short-term Investments of $7.4 million as of Q3 2025, which was down 9478.92% from $47.5 million recorded in Q2 2025.
  • Over the past 5 years, Prelude Therapeutics' Short-term Investments peaked at $177.2 million during Q1 2024, and registered a low of $7.4 million during Q3 2025.